Oncology Institute releases Q2 2023 results and 2023 guidance; no specific figures in filing text

Oncology Institute, Inc.

2023-Q2 EPS reported -$0.52 revenue$156,416,000

Company furnished slide presentation with Q2 and H1 2023 financial results on August 10, 2023.
Management provided updated business guidance for the year ending December 31, 2023.
No revenue, EPS, or other numeric details are extractable from the available filing exhibits.
Tickers: TOI (common stock) and TOIIW (warrants).

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Oncology Institute, Inc. reported financial results for the three months ended June 30, 2023.

Period: the three months ended June 30, 2023
Result: reported results

Exact text from the filing

On August 10, 2023, The Oncology Institute, Inc. (the "Company") issued a slide presentation which includes the Company's financial results for the three months and six months ended June 30, 2023 and certain other financial information.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Oncology Institute, Inc. reported financial results for the six months ended June 30, 2023.

Period: the six months ended June 30, 2023
Result: reported results

Exact text from the filing

On August 10, 2023, The Oncology Institute, Inc. (the "Company") issued a slide presentation which includes the Company's financial results for the three months and six months ended June 30, 2023 and certain other financial information.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

Oncology Institute, Inc. filing history →

Source: SEC EDGAR

accession 0001799191-23-000037

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.